Norris Medicines Intrinsic Value
Norris Medicines (NORRIS) median intrinsic value is ₹9.28 from 2 valuation models (range ₹6–₹9), vs current price ₹16.34 — -43.2% downside (Trading Above Calculated Value), margin of safety -76.1%. Analyse Norris Medicines shareholding analysis to track promoter, FII and institutional holdings.
NORRIS Valuation Methods Summary — DCF, Graham Number & P/E
Norris Medicines intrinsic value across 2 models vs current price ₹16.34 — upside/downside and value range per method. Read NORRIS dividend payout details for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Revenue Multiple Method | revenue | ₹6.40 | ₹5.76 - ₹7.04 | -60.8% | Revenue/Share: ₹8.00, P/S: 0.8x |
| Simple DCF (5Y) | dcf | ₹9.28 | ₹7.42 - ₹11.14 | -43.2% | CF Growth: 5.0%, Discount: 15% |
NORRIS Intrinsic Value vs Market Price — All Valuation Models
Norris Medicines fair value range ₹6–₹9 vs current market price ₹16.34 across 2 valuation models. For current market price and key ratios, visit NORRIS share price screener.
NORRIS Intrinsic Value Analysis — Undervalued or Overvalued?
Norris Medicines median intrinsic value ₹9.28, current price ₹16.34 — Trading Above Calculated Value by 43.2%, margin of safety -76.1%.
What is the intrinsic value of NORRIS?
Based on our comprehensive analysis using 2 different valuation methods, the estimated intrinsic value of Norris Medicines (NORRIS) is ₹9.28 (median value). With the current market price of ₹16.34, this represents a -43.2% variance from our estimated fair value.
The valuation range spans from ₹6.40 to ₹9.28, indicating ₹6.40 - ₹9.28.
Is NORRIS undervalued or overvalued?
Based on our multi-method analysis, Norris Medicines (NORRIS) appears to be trading above calculated value by approximately 43.2%.
NORRIS Financial Health — Key Ratios vs Industry Benchmarks
Norris Medicines financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.32 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Operating Margin | -1.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.57x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
NORRIS Cash Flow Quality — Operating & Free Cash Flow
Norris Medicines operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹-1 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |